SCHEMBL19424600

SCHEMBL19424600

Cc1cc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CC(C)(C)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)ccc1NCCC#N

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 19/20 0.78
▸ HDAC1 Q13547 3/20 0.72
▸ HDAC6 Q9UBN7 3/20 0.72
▸ NSD2 O96028 1/20 0.71
▸ ADORA3 P0DMS8 1/20 0.71
▸ CYP2C9 P11712 1/20 0.71
▸ ADRA2C P18825 1/20 0.71
▸ SLC6A2 P23975 1/20 0.71
▸ BID P55957 1/20 0.71
▸ SLC6A3 Q01959 1/20 0.71
▸ BCL2L1 Q07817 1/20 0.71
▸ MCL1 Q07820 1/20 0.71
▸ ASPH Q12797 1/20 0.71
▸ BCL2L2 Q92843 1/20 0.71
▸ BAD Q92934 1/20 0.71
▸ NSD1 Q96L73 1/20 0.71
▸ NSD3 Q9BZ95 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19424472 0.94 BCL2 (0.86) BCL2HDAC1HDAC6NSD2ADORA3
SCHEMBL30313954 0.93 BCL2 (0.86) BCL2HDAC1HDAC6NSD2ADORA3
SCHEMBL1699808 0.93 BCL2 (0.86) BCL2HDAC1HDAC6NSD2ADORA3
SCHEMBL19424446 0.92 BCL2 (0.79) BCL2HDAC1HDAC6NSD2ADORA3
SCHEMBL19424558 0.92 BCL2 (0.87) BCL2HDAC1HDAC6
SCHEMBL19424730 0.92 BCL2 (0.76) BCL2
SCHEMBL19424657 0.91 BCL2 (0.88) BCL2NSD2ADORA3CYP2C9ADRA2C
SCHEMBL19424470 0.90 BCL2 (0.76) BCL2
SCHEMBL19424458 0.90 BCL2 (0.77) BCL2NSD2ADORA3CYP2C9ADRA2C
SCHEMBL19424518 0.90 BCL2 (0.87) BCL2NSD2ADORA3CYP2C9ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 BCL2 520/4885HDAC1 382/4885HDAC6 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback